Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 216.8 Million EUR | -37.97% |
| 2022 | 349.5 Million USD | 80.34% |
| 2021 | 193.8 Million EUR | -11.87% |
| 2020 | 219.9 Million EUR | 9.73% |
| 2019 | 200.4 Million EUR | -0.74% |
| 2018 | 201.9 Million EUR | -10.66% |
| 2017 | 226 Million EUR | -9.24% |
| 2016 | 249 Million EUR | 19.6% |
| 2015 | 208.2 Million EUR | -1.47% |
| 2014 | 211.3 Million EUR | 2.47% |
| 2013 | 206.2 Million EUR | -0.34% |
| 2012 | 206.9 Million EUR | -1.24% |
| 2011 | 209.5 Million EUR | 13.43% |
| 2010 | 184.7 Million EUR | 21.99% |
| 2009 | 151.4 Million EUR | 11.08% |
| 2008 | 136.3 Million EUR | -5.28% |
| 2007 | 143.9 Million EUR | 116.07% |
| 2006 | 66.6 Million EUR | -49.2% |
| 2005 | 131.1 Million EUR | 44.86% |
| 2004 | 90.5 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 43.8 Million EUR | -41.76% |
| 2024 Q2 | 52 Million EUR | 18.72% |
| 2024 Q3 | 160.8 Million EUR | 209.23% |
| 2023 Q1 | 43.8 Million USD | 38.61% |
| 2023 FY | 216.8 Million EUR | -37.97% |
| 2023 Q4 | 75.2 Million EUR | 22.48% |
| 2023 Q3 | 61.4 Million USD | 68.68% |
| 2023 Q2 | 36.4 Million USD | -16.89% |
| 2022 Q3 | 194.5 Million EUR | 194.25% |
| 2022 FY | 349.5 Million USD | 80.34% |
| 2022 Q2 | 66.1 Million EUR | 15.36% |
| 2022 Q4 | 31.6 Million USD | -83.75% |
| 2022 Q1 | 57.3 Million EUR | 74.7% |
| 2021 Q4 | 32.8 Million EUR | -27.75% |
| 2021 Q1 | 59.6 Million EUR | 133.73% |
| 2021 Q2 | 56 Million EUR | -6.04% |
| 2021 Q3 | 45.4 Million EUR | -18.93% |
| 2021 FY | 193.8 Million EUR | -11.87% |
| 2020 Q3 | 51.4 Million EUR | -32.01% |
| 2020 Q1 | 67.4 Million EUR | 49.12% |
| 2020 Q2 | 75.6 Million EUR | 12.17% |
| 2020 FY | 219.9 Million EUR | 9.73% |
| 2020 Q4 | 25.5 Million EUR | -50.39% |
| 2019 Q2 | 40.8 Million EUR | -4.67% |
| 2019 Q1 | 42.8 Million EUR | -19.4% |
| 2019 FY | 200.4 Million EUR | -0.74% |
| 2019 Q4 | 45.2 Million EUR | -36.87% |
| 2019 Q3 | 71.6 Million EUR | 75.49% |
| 2018 FY | 201.9 Million EUR | -10.66% |
| 2018 Q4 | 53.1 Million EUR | 54.81% |
| 2018 Q3 | 34.3 Million EUR | -81.53% |
| 2018 Q2 | 185.7 Million EUR | 225.22% |
| 2018 Q1 | 57.1 Million EUR | 3.44% |
| 2017 Q4 | 55.2 Million EUR | 25.17% |
| 2017 Q3 | 44.1 Million EUR | -21.95% |
| 2017 Q2 | 56.5 Million EUR | -19.63% |
| 2017 Q1 | 70.3 Million EUR | 47.69% |
| 2017 FY | 226 Million EUR | -9.24% |
| 2016 Q3 | 72.5 Million EUR | 10.35% |
| 2016 Q4 | 47.6 Million EUR | -34.34% |
| 2016 Q1 | 63.3 Million EUR | 60.66% |
| 2016 Q2 | 65.7 Million EUR | 3.79% |
| 2016 FY | 249 Million EUR | 19.6% |
| 2015 Q3 | 45.3 Million EUR | -21.49% |
| 2015 FY | 208.2 Million EUR | -1.47% |
| 2015 Q4 | 39.4 Million EUR | -13.02% |
| 2015 Q2 | 57.7 Million EUR | -12.18% |
| 2015 Q1 | 65.7 Million EUR | 61.03% |
| 2014 Q3 | 49.8 Million EUR | -26.76% |
| 2014 Q1 | 52.6 Million EUR | -5.57% |
| 2014 Q4 | 40.8 Million EUR | -18.07% |
| 2014 FY | 211.3 Million EUR | 2.47% |
| 2014 Q2 | 68 Million EUR | 29.28% |
| 2013 Q1 | 55.6 Million EUR | 29.6% |
| 2013 FY | 206.2 Million EUR | -0.34% |
| 2013 Q2 | 45.9 Million EUR | -17.45% |
| 2013 Q4 | 55.7 Million EUR | 13.44% |
| 2013 Q3 | 49.1 Million EUR | 6.97% |
| 2012 FY | 206.9 Million EUR | -1.24% |
| 2012 Q1 | 59.1 Million EUR | 30.75% |
| 2012 Q4 | 42.9 Million EUR | -24.2% |
| 2012 Q3 | 56.6 Million EUR | 16.22% |
| 2012 Q2 | 48.7 Million EUR | -17.6% |
| 2011 Q1 | 68.5 Million EUR | 86.65% |
| 2011 Q3 | 47.8 Million EUR | -0.42% |
| 2011 Q4 | 45.2 Million EUR | -5.44% |
| 2011 FY | 209.5 Million EUR | 13.43% |
| 2011 Q2 | 48 Million EUR | -29.93% |
| 2010 Q3 | 51.6 Million EUR | 17.27% |
| 2010 Q4 | 36.7 Million EUR | -28.88% |
| 2010 Q1 | 52.4 Million EUR | 58.79% |
| 2010 FY | 184.7 Million EUR | 21.99% |
| 2010 Q2 | 44 Million EUR | -16.03% |
| 2009 Q2 | 36.2 Million EUR | -13.6% |
| 2009 FY | 151.4 Million EUR | 11.08% |
| 2009 Q4 | 33 Million EUR | -18.11% |
| 2009 Q3 | 40.3 Million EUR | 11.33% |
| 2009 Q1 | 41.9 Million EUR | 0.0% |
| 2008 FY | 136.3 Million EUR | -5.28% |
| 2007 FY | 143.9 Million EUR | 116.07% |
| 2006 FY | 66.6 Million EUR | -49.2% |
| 2005 FY | 131.1 Million EUR | 44.86% |
| 2004 FY | 90.5 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | 96.359% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 97.298% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | 73.908% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 483.635% |
| Novartis AG | 14.85 Billion USD | 98.54% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -20.642% |